The healthcare arena continues to attract capital, yet the way an exchange-traded fund (ETF) is built can tilt the balance between reward and risk. Two products dominate the conversation for investors seeking exposure to medical innovation: the Simplify Health Care ETF (ticker PINK) and the VanEck Biotech ETF (ticker BBH). While both sit under the broad health umbrella, their management styles, fee structures and portfolio depths differ enough to merit a thorough side-by-side comparison, especially as the industry approaches a pivotal 2027 horizon.
Cost structure and assets under management
When fee efficiency matters, the VanEck Biotech ETF enjoys a modest expense ratio of 0.35%, undercutting the specialty-fund average. In contrast, Simplify’s actively managed vehicle charges 0.51%, reflecting the additional research and portfolio turnover involved in its broader mandate. Share prices as of November 2, 2026, sit at $254.50 for BBH and $40.08 for PINK, supporting a total AUM of $536.37 million and $350.56 million respectively. Dividend-seeking investors will note that Simplify offers a higher trailing-12-month yield of roughly 0.7%, versus BBH’s 0.37%, though the latter’s lower expense ratio provides a long-term cost advantage.
Portfolio makeup and concentration
Simplify adopts a diversified stance, spreading capital across roughly 52 holdings that touch biotechnology, pharmaceuticals, medical devices and health services. Approximately 90 % of its assets remain within healthcare, while the remainder leaks into consumer discretionary, materials and industrial stocks. Its top three positions—United Therapeutics (8.45 %), Arcutis Biotherapeutics (8.42 %) and Johnson & Johnson (7.58 %)—illustrate a balanced tilt toward both emerging and established players.
VanEck’s approach is far narrower, tracking the MVIS US Listed Biotech 25 Index. The fund holds exactly 25 biotechnology names, with no exposure beyond the sector. The three largest stakes—Amgen (16.56 %), Gilead Sciences (14.36 %) and Vertex Pharmaceuticals (8.19 %)—account for nearly 40 % of the portfolio, underscoring a concentration risk but also a focus on companies possessing deep pipelines and sizeable cash flows.
Performance track record and risk metrics
Over the past year, BBH posted a robust 41.2 % total return, outpacing PINK’s 21.1 %. The five-year window tells a similar tale: a $1,000 investment in VanEck would have grown to $1,554, whereas the Simplify fund would sit at $1,285. Drawdown analysis reveals distinct risk profiles; BBH suffered a maximum 34.6 % decline in the last five years, while PINK’s peak loss was 18.7 %. Both funds carry betas hovering around 0.70, indicating comparable sensitivity to broader market moves.
Outlook for 2027 and positioning choice
Looking ahead, the healthcare sector is poised for mixed signals. Rising demand for novel therapies and a potential resurgence in biotech mergers promise upside, yet pressures on drug pricing, looming patent cliffs and volatile interest-rate expectations could strain margins. In this environment, the VanEck Biotech ETF’s focus on seasoned growers with diversified drug portfolios may provide a steadier footing, especially given its lower expense ratio and exposure to companies equipped to fund next-generation research.
Conversely, Simplify’s broader canvas offers flexibility to capture breakthroughs in medical devices or services that may not yet be reflected in pure biotech indices. The trade-off is higher management fees and the added uncertainty of active stock selection. Investors comfortable with a more diversified health exposure and willing to absorb the extra cost might favor PINK, while those seeking concentrated, cost-efficient biotech exposure may lean toward BBH.
